36 citations,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
7 citations,
September 2021 in “Antimicrobial Agents and Chemotherapy” Olorofim effectively treats fungal skin infections.
253 citations,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
20 citations,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
January 2018 in “Practical diabetes” Leflunomide is effective for rheumatoid arthritis but has significant side effects.
29 citations,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
6 citations,
September 2017 in “Multiple Sclerosis and Related Disorders” Nail loss may be a side effect of the MS drug teriflunomide.
70 citations,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
37 citations,
September 2017 in “Reumatología Clínica” Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.
16 citations,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
13 citations,
January 1999 in “Postgraduate Medicine” New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
1 citations,
April 2019 in “Reumatología Clínica (English Edition)” Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
39 citations,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
May 2024 in “Scientific African” Three natural compounds from Ghanaian plants may help treat BPH and alopecia.
72 citations,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
June 2017 in “Journal of The American Academy of Dermatology” Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
May 2017 in “Journal of The American Academy of Dermatology” 595 nm pulsed dye laser is a cost-effective treatment for nonmelanoma skin cancer with a low recurrence rate.
113 citations,
December 2000 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” KGF and activin are crucial for skin healing and repair.
December 2008 in “Enzyme and Microbial Technology” New patents include innovations in skin and hair care, disease treatment, plant stress tolerance, and protein purification.